Abstract
Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications. The product was developed by Centocor and Janssen Pharmaceutical KK (Johnson & Johnson subsidiaries), in collaboration with Schering-Plough and Mitsubishi Tanabe Pharma. Golimumab faces numerous protein therapeutic competitors on the market, but, as the first patient-administered, once-monthly dosed anti-TNFalpha drug, it will likely be an attractive option for patients.
MeSH terms
-
Animals
-
Antibodies, Monoclonal* / administration & dosage
-
Antibodies, Monoclonal* / adverse effects
-
Antibodies, Monoclonal* / immunology
-
Antibodies, Monoclonal* / therapeutic use
-
Arthritis, Psoriatic* / drug therapy
-
Arthritis, Psoriatic* / immunology
-
Arthritis, Rheumatoid* / drug therapy
-
Arthritis, Rheumatoid* / immunology
-
Clinical Trials as Topic
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Female
-
Humans
-
Infant, Newborn
-
Male
-
Methotrexate / administration & dosage
-
Methotrexate / therapeutic use
-
Pregnancy
-
Spondylitis, Ankylosing* / drug therapy
-
Spondylitis, Ankylosing* / immunology
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / immunology*
Substances
-
Antibodies, Monoclonal
-
Tumor Necrosis Factor-alpha
-
golimumab
-
Methotrexate